Matsuyama M, Hayama T, Funao K, Tsuchida K, Takemoto Y, Sugimura K, Kawahito Y, Sano H, Nakatani T, Yoshimura R
Department of Urology, Osaka City University Graduate School of Medicine, 1-4-3 Asahimachi, Abeno-ku, Osaka 545-8585, Japan.
Transplant Proc. 2006 Sep;38(7):2199-200. doi: 10.1016/j.transproceed.2006.06.077.
Renal ischemia-reperfusion (I/R) injury during renal transplantation is a significant cause of renal dysfunction. The pathological role of free radicals in this process is a major concern. We investigated the effect of a free radical scavenger, edaravone (MCI-186), in renal I/R injury. Male Lewis rats (270 to 320 g) were used for the model. The right kidney was harvested and left renal artery and vein were clamped as laparotomy. The kidney was reperfused after 90 minutes of ischemia. Edaravone (10 mg/kg) was delivered intravenously before ischemia and after reperfusion to prevent the neutrophil activation. In the nontreatment I/R group, no rat survived beyond 4 days. However, in the edaravone I/R treatment group, one among five rats survived more than 7 days. These results suggested that treatment with edaravone ameliorated renal I/R injury, and that the agent has the potential to ameliorate preservation injury in renal transplantation.
肾移植过程中的肾缺血再灌注（I/R）损伤是肾功能障碍的一个重要原因。自由基在这一过程中的病理作用是人们主要关注的问题。我们研究了自由基清除剂依达拉奉（MCI-186）对肾I/R损伤的影响。雄性Lewis大鼠（体重270至320克）用于建立模型。切除右肾，剖腹手术时夹闭左肾动脉和静脉。缺血90分钟后对肾脏进行再灌注。在缺血前和再灌注后静脉注射依达拉奉（10毫克/千克）以防止中性粒细胞活化。在未治疗的I/R组中，没有大鼠存活超过4天。然而，在依达拉奉I/R治疗组中，五只大鼠中有一只存活超过7天。这些结果表明，依达拉奉治疗可改善肾I/R损伤，且该药物有改善肾移植中保存损伤的潜力。
